Sign up to access all valuation multiples
Lunai Bioworks Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
2011
25
Last FY Revenue n/a
Last FY EBITDA -$78.1M
$54.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Lunai Bioworks achieved revenue of n/a and an EBITDA of -$78.1M.
Lunai Bioworks expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lunai Bioworks valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$78.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$27.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$80.7M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | $2.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, Lunai Bioworks's stock price is $0.
Lunai Bioworks has current market cap of $49.3M, and EV of $54.7M.
See Lunai Bioworks trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $54.7M | $49.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, Lunai Bioworks has market cap of $49.3M and EV of $54.7M.
Lunai Bioworks's trades at n/a EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate Lunai Bioworks's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lunai Bioworks's P/E ratio is not available.
See valuation multiples for Lunai Bioworks and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $49.3M | XXX | $49.3M | XXX | XXX | XXX |
| EV (current) | $54.7M | XXX | $54.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -2.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLunai Bioworks's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
Lunai Bioworks's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lunai Bioworks's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lunai Bioworks and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lunai Bioworks acquired XXX companies to date.
Last acquisition by Lunai Bioworks was XXXXXXXX, XXXXX XXXXX XXXXXX . Lunai Bioworks acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Lunai Bioworks founded? | Lunai Bioworks was founded in 2011. |
| Where is Lunai Bioworks headquartered? | Lunai Bioworks is headquartered in United States of America. |
| How many employees does Lunai Bioworks have? | As of today, Lunai Bioworks has 25 employees. |
| Who is the CEO of Lunai Bioworks? | Lunai Bioworks's CEO is Mr. David Weinstein. |
| Is Lunai Bioworks publicy listed? | Yes, Lunai Bioworks is a public company listed on NAS. |
| What is the stock symbol of Lunai Bioworks? | Lunai Bioworks trades under RENB ticker. |
| When did Lunai Bioworks go public? | Lunai Bioworks went public in 2014. |
| Who are competitors of Lunai Bioworks? | Similar companies to Lunai Bioworks include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Lunai Bioworks? | Lunai Bioworks's current market cap is $49.3M |
| Is Lunai Bioworks profitable? | Yes, Lunai Bioworks is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
